Table 5 Larger phase 2 studies of new... | American Society of Hematology

Table 5

Larger phase 2 studies of new agents with response by subtype

Subtype	Overall response rate by common subtype
Subtype	Pralatrexate²⁸	Romidepsin²⁷	Belinostat^48,58	Brentuximab vedotin^28,30
PTCL-NOS	31%	29%	23%	33%
AITL	8%	30%	46%	54%
ALCL	29%	24%	15%	86%

Subtype	Overall response rate by common subtype
Subtype	Pralatrexate²⁸	Romidepsin²⁷	Belinostat^48,58	Brentuximab vedotin^28,30
PTCL-NOS	31%	29%	23%	33%
AITL	8%	30%	46%	54%
ALCL	29%	24%	15%	86%